NeOnc Technologies Holdings Inc
NTHI
View Detailed Chart
7.300USD
+0.290+4.14%
Market hours （ET）Quotes delayed by 15 min
142.16MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.14%
5 Days
-28.50%
1 Month
+24.57%
6 Months
+71.56%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
TradingKey Stock Score of NeOnc Technologies Holdings Inc
Currency: USD Updated: 2025-12-19Key Insights
NeOnc Technologies Holdings Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 224/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NeOnc Technologies Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
NeOnc Technologies Holdings Inc Highlights
StrengthsRisks
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 315.00% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 83.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 83.00K.
Fairly Valued
The company’s latest PE is -2.69, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.61M shares, increasing 44.32% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 140.91K shares of this stock.
NeOnc Technologies Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NeOnc Technologies Holdings Inc Info
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Ticker SymbolNTHI
CompanyNeOnc Technologies Holdings Inc
CEOHeshmatpour (Amir F)
Websitehttps://neonc.com/
FAQs
What is the current price of NeOnc Technologies Holdings Inc (NTHI)?
The current price of NeOnc Technologies Holdings Inc (NTHI) is 7.300.
What is the symbol of NeOnc Technologies Holdings Inc?
The ticker symbol of NeOnc Technologies Holdings Inc is NTHI.
What is the 52-week high of NeOnc Technologies Holdings Inc?
The 52-week high of NeOnc Technologies Holdings Inc is 25.000.
What is the 52-week low of NeOnc Technologies Holdings Inc?
The 52-week low of NeOnc Technologies Holdings Inc is 3.200.
What is the market capitalization of NeOnc Technologies Holdings Inc?
The market capitalization of NeOnc Technologies Holdings Inc is 142.16M.
What is the net income of NeOnc Technologies Holdings Inc?
The net income of NeOnc Technologies Holdings Inc is -11.90M.
Is NeOnc Technologies Holdings Inc (NTHI) currently rated as Buy, Hold, or Sell?
According to analysts, NeOnc Technologies Holdings Inc (NTHI) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of NeOnc Technologies Holdings Inc (NTHI)?
The Earnings Per Share (EPS TTM) of NeOnc Technologies Holdings Inc (NTHI) is -2.602.
Related Instruments
+0.10%
-0.23%
-0.92%
+0.01%
+0.35%
+1.41%
+0.69%
-0.88%
-0.32%
+0.28%
-0.52%
+0.07%
+0.06%
+0.30%
+0.16%
+0.61%
+1.33%
0.00%
+2.77%
+0.14%Popular Symbols
